FDA broadens label for Amgen's Uplizna as it enters rare disease competition
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
本文は利用できません。元の情報源をご確認ください。
FDA broadens label for Amgen's Uplizna as it enters rare disease competition